Home > Publications database > The Safety Profile of Vitamin D Supplements Using Real-World Data from 445,493 Participants of the UK Biobank: Slightly Higher Hypercalcemia Prevalence but Neither Increased Risks of Kidney Stones nor Atherosclerosis. > print

001     291917
005     20241110013656.0
024 7 _ |a 10.3390/nu16142251
|2 doi
024 7 _ |a pmid:39064694
|2 pmid
024 7 _ |a pmc:PMC11279740
|2 pmc
024 7 _ |a altmetric:168278288
|2 altmetric
037 _ _ |a DKFZ-2024-01529
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Sha, Sha
|0 P:(DE-He78)1d6f6305a65e2f7de2c7fbffbae83780
|b 0
|e First author
|u dkfz
245 _ _ |a The Safety Profile of Vitamin D Supplements Using Real-World Data from 445,493 Participants of the UK Biobank: Slightly Higher Hypercalcemia Prevalence but Neither Increased Risks of Kidney Stones nor Atherosclerosis.
260 _ _ |a Basel
|c 2024
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1722250169_32764
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C070#LA:C070#LA:C120#
520 _ _ |a Background: Potential calcium-related adverse events of vitamin D supplement use have not been addressed in large-scale, real-world data so far. Methods: Leveraging data from the UK Biobank, encompassing 445,493 individuals aged 40-69, we examined associations of high 25-hydroxyvitamin (25(OH)D) levels ≥ 100 nmol/L and vitamin D supplementation with hypercalcemia (serum calcium > 2.6 mmol/L), kidney stones, and atherosclerosis assessments (pulse wave arterial stiffness index and carotid intima-medial thickness). Regression models were comprehensively adjusted for 49 covariates. Results: Approximately 1.5% of the participants had high 25(OH)D levels, 4.3% regularly used vitamin D supplements, and 20.4% reported regular multivitamin use. At baseline, the hypercalcemia prevalence was 1.6%, and 1.1% was diagnosed with kidney stones during follow-up. High 25(OH)D levels were neither associated with calcium-related adverse events nor atherosclerosis assessments. Vitamin D and multivitamin supplementation were associated with an increased prevalence of hypercalcemia (odds ratios and 95% confidence intervals: 1.46 [1.32-1.62] and 1.11 [1.04-1.18], respectively) but were neither associated with atherosclerosis nor future kidney stones. Conclusions: High 25(OH)D levels observable in routine care were not associated with any adverse outcome. Vitamin D users have a slightly higher prevalence of hypercalcemia, possibly due to co-supplementation with calcium, but without a higher atherosclerosis prevalence or risk of kidney stones.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a adverse events
|2 Other
650 _ 7 |a atherosclerosis
|2 Other
650 _ 7 |a hypercalcemia
|2 Other
650 _ 7 |a kidney stone risk
|2 Other
650 _ 7 |a real-world evidence
|2 Other
650 _ 7 |a serum 25-hydroxyvitamin D levels
|2 Other
650 _ 7 |a vitamin D supplementation
|2 Other
650 _ 7 |a Vitamin D
|0 1406-16-2
|2 NLM Chemicals
650 _ 7 |a 25-hydroxyvitamin D
|0 A288AR3C9H
|2 NLM Chemicals
650 _ 7 |a Calcium
|0 SY7Q814VUP
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Hypercalcemia: epidemiology
|2 MeSH
650 _ 2 |a Hypercalcemia: chemically induced
|2 MeSH
650 _ 2 |a Vitamin D: analogs & derivatives
|2 MeSH
650 _ 2 |a Vitamin D: blood
|2 MeSH
650 _ 2 |a Vitamin D: administration & dosage
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Dietary Supplements: adverse effects
|2 MeSH
650 _ 2 |a United Kingdom: epidemiology
|2 MeSH
650 _ 2 |a Kidney Calculi: epidemiology
|2 MeSH
650 _ 2 |a Kidney Calculi: blood
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Atherosclerosis: epidemiology
|2 MeSH
650 _ 2 |a Atherosclerosis: etiology
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Prevalence
|2 MeSH
650 _ 2 |a Biological Specimen Banks
|2 MeSH
650 _ 2 |a Risk Factors
|2 MeSH
650 _ 2 |a Calcium: blood
|2 MeSH
650 _ 2 |a Calcium: administration & dosage
|2 MeSH
650 _ 2 |a UK Biobank
|2 MeSH
700 1 _ |a Degen, Miriam
|0 P:(DE-He78)32395dd61ce265f1f29942fadf07e669
|b 1
|u dkfz
700 1 _ |a Vlaski, Tomislav
|0 P:(DE-He78)236d02bfaad255f19aa65e9cd9d63a8a
|b 2
|u dkfz
700 1 _ |a Fan, Ziwen
|0 P:(DE-He78)79862c68074f8d78156f06f6e3c9801c
|b 3
|u dkfz
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 4
|e Last author
|u dkfz
700 1 _ |a Schöttker, Ben
|0 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
|b 5
|e Last author
|u dkfz
773 _ _ |a 10.3390/nu16142251
|g Vol. 16, no. 14, p. 2251 -
|0 PERI:(DE-600)2518386-2
|n 14
|p 2251
|t Nutrients
|v 16
|y 2024
|x 2072-6643
856 4 _ |u https://inrepo02.dkfz.de/record/291917/files/nutrients-16-02251-v2.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/291917/files/nutrients-16-02251-v2.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:inrepo02.dkfz.de:291917
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)1d6f6305a65e2f7de2c7fbffbae83780
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)32395dd61ce265f1f29942fadf07e669
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)236d02bfaad255f19aa65e9cd9d63a8a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)79862c68074f8d78156f06f6e3c9801c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NUTRIENTS : 2022
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:01:20Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:01:20Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T15:01:20Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2023-04-12T15:01:20Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-23
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-23
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NUTRIENTS : 2022
|d 2023-08-23
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-23
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-23
920 2 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 2 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 1
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
920 0 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21